Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24861374 | 0.92 | MEN1 (0.33) | KDM4E | |
| SCHEMBL24171293 | 0.87 | SLC6A4 (0.41) | KDM4ESLC6A4TAS1R3TAS1R1 | |
| SCHEMBL1277087 | 0.83 | SLC6A4 (0.42) | KDM4ERECQLSLC6A4CA2 | |
| SCHEMBL15463288 | 0.82 | KDM4E (0.35) | KDM4ERECQLSLC6A4CA2ABCB11 | |
| SCHEMBL13976255 | 0.76 | MEN1 (0.41) | — | |
| SCHEMBL12737483 | 0.76 | CYP3A4 (0.35) | KDM4ERECQLSLC6A4CA2ABCB11 | |
| SCHEMBL24861284 | 0.76 | KDM4E (0.37) | KDM4E | |
| SCHEMBL25083919 | 0.74 | CYP3A4 (0.37) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL21839006 | 0.74 | KDM4E (0.40) | KDM4ERECQLSLC6A4CA2 | |
| SCHEMBL22861638 | 0.74 | KDM4E (0.40) | KDM4ERECQLSLC6A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | KDM4E 3367/4885RECQL 3115/4885SLC6A4 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.